Participants are randomly assigned to receive either the bicarbonate solution or the placebo during labor and are followed through delivery. Researchers will record whether delivery required the defined assisted methods and will also note if the newborn needs to stay in a neonatal intensive care unit within the first day, as well as the mother’s reported birth experience using the Childbirth Experience Questionnaire. The trial continues only for the duration of labor and the immediate postpartum period, after which the collected data are analyzed.

The purpose of the trial is to see whether the medication is safe and can help shrink or stop the growth of the cancer. Participants will receive the infusion in a series of treatment cycles, with regular check‑ups to watch for side effects and to see how the tumor responds. Throughout the study, doctors will monitor health and any changes in the cancer, using simple examinations and scans, to determine if the drug shows a beneficial effect.

The purpose of the study is to assess the long‑term safety and clinical benefit of the medication. Participants will take the granules by mouth each day for an extended period and will attend regular visits where doctors will check how they are feeling and perform simple tests.

During the visits, several simple assessments are done: a muscle‑function questionnaire called NSAD, a walking speed test over ten meters known as the 10MWT, a breathing test that measures how much air can be exhaled called FVC, an upper‑limb function test named PUL 2.0, a walking distance test over one hundred meters called 100MTT, and a blood test that measures a protein called CK which indicates muscle damage. These checks help researchers understand how the medication affects muscle strength, movement, and overall health over time.

Participants who have finished first‑line chemotherapy and are either in complete remission (no detectable cancer) or have stable disease are randomly assigned to one of the two groups. They take the study medication daily for a defined period while regular check‑ups, scans, and questionnaires about quality of life are performed. The study follows each participant for several years to record any return of cancer, new health problems, or death, and the information is used to compare the two treatment approaches.

Participants are randomly assigned to receive either the new combination or the standard regimen; the new drugs are given by IV infusion on scheduled days while the oral pills are taken at home. The standard‑of‑care arm receives the physician‑chosen drugs (such as elotuzumab, carfilzomib or daratumumab) using the usual dosing routes. Throughout the study, blood work, imaging and a bone‑marrow test reviewed by an independent review committee (IRC) using criteria from the International Myeloma Working Group (IMWG) are performed to follow the disease. Additional outcomes include measures such as overall survival (OS), very good partial response (VGPR), overall response rate (ORR), time to first response (TTR), time to deepest response (TTBR) and duration of response (DOR). Safety is checked with standard grading systems from the NCI (CTCAE) and the ASTCT for side‑effects such as cytokine release syndrome (CRS), immune‑cell neurotoxicity (ICANS) and severe inflammation syndromes (HLH, IEC-HS). Patients also complete quality‑of‑life questionnaires from the EORTC (QLQ-MY20, QLQ-C30) and the FACTG tool, and report symptoms using the PRO-CTCAE system during regular visits until the disease progresses or the study ends.

The purpose of the study is to determine whether stopping long‑term aspirin in this population is not worse than continuing it for overall health outcomes. Participants will be randomly assigned to either keep taking aspirin or to receive a harmless tablet that looks the same but contains no active drug (placebo). The study will follow participants for several years, checking in at regular intervals.

During the follow‑up, researchers will record events such as cardiovascular death, fatal bleeding, intracranial bleeding, ischemic stroke, MI and other serious bleeding problems, as well as less severe issues like peptic ulcer, angina, and overall quality of life. The information collected will help decide if stopping aspirin is a safe option for older adults with stable heart disease.

The aim is to see whether the combination of the medication and psychotherapy leads to greater improvement in mood compared with the medication plus basic support or with the usual treatment that patients normally receive (standard of care). Volunteers will attend an initial screening, take the capsule in a comfortable setting, meet with a therapist for several sessions, and then return for regular check‑ins over the next year to monitor mood, sleep and overall well‑being. Terms such as “psychotherapy” refer to professional talk therapy that helps people process thoughts and feelings, while “basic support” means brief guidance without the full therapeutic program.

The purpose of this study is to learn how the body processes ANX005, how it affects certain proteins and defense system activity in the blood, and whether it is safe and helpful for people with Guillain-Barré syndrome. The study will look at how the medicine moves through the body and how long it stays there, as well as how it changes the levels of C1q protein and the activity of the complement pathway, which is part of the body’s defense system. The study will also measure changes in muscle strength using a scoring system.

Participants in this study will receive a single dose of ANX005 and will be monitored for several weeks afterward. During this time, blood samples will be collected to measure the levels of the medicine and to see how it affects certain proteins in the blood. The study will also track improvements in muscle strength and overall ability to move and function. All participants will know they are receiving the active treatment, as this is not a comparison study with placebo. The study is expected to last until mid-2026.

The purpose of the study is to evaluate whether the combination of the new protein and the chemotherapy works well and is safe for these patients. Participants receive the study drug by infusion (a slow drip into a vein) together with chemotherapy cycles given every few weeks. The treatment period lasts several months, with regular visits to check for side effects and to see how the tumor responds.

After the treatment phase, children are followed for a period of time to monitor disease behavior and record any long‑term effects. Blood tests, imaging scans, and physical examinations are used to assess progress, and any problems are managed by the medical team. The information gathered will help determine if this approach could become a new standard option for children with this serious condition.

The purpose of the trial is to determine whether NXT007 works at least as well as Emicizumab in preventing bleeds. Participants receive regular injections for several months and attend scheduled visits where doctors check their health, collect blood samples, and ask about daily activities and quality of life. The main way the study measures success is by counting the average number of bleeding episodes that need treatment each year, called the annualized number of treated bleeds.

Throughout the study, safety is closely watched. Researchers look for any side effects such as reactions at the injection site, allergic responses, or signs of clotting problems. Participants also complete simple questionnaires about how their condition affects everyday life, helping to assess both the medical and personal impact of the treatments.

Participants may receive one of several study medicines: an oral tablet called ibrutinib, an oral capsule named zanubrutinib, an intravenous infusion of linvoseltamab, a subcutaneous injection (under the skin) of elranatamab, a subcutaneous injection of teclistamab, or a subcutaneous injection of talquetamab. Oral medicines are taken by mouth, while the infusion is given through a vein and the injections are placed just under the skin. Each medication is given at a specific dose that is determined by the study plan.

People are randomly assigned to receive one of the medicines and are followed for a period of time with regular clinic visits, blood tests, and health questionnaires. Throughout the study, researchers track how long participants live (called overall survival) and other health outcomes such as disease progression and quality of life, while also monitoring for any side effects.

The purpose of the trial is to determine whether a single intrathecal injection of the study drug into the fluid surrounding the spinal cord in the lower back can improve leg function. Participants will receive the injection once and then be monitored over several years with regular visits to assess changes in walking and other motor skills using a standard motor‑function test. Throughout the study, safety checks and simple questionnaires will be used to track any side effects and overall health.

The purpose of the study is to determine whether Admilparant can be used safely over an extended period without causing serious side effects. Participants will take the medication each day and will attend regular visits where healthcare staff will check vital signs such as blood pressure and heart rate, review simple blood tests, and perform a basic heart test known as an ECG, which records the heart’s electrical activity. Any side effects that arise will be recorded and evaluated.

The study will continue for many months to gather enough information about safety and tolerability. Throughout the study, participants will be asked to report any new symptoms or problems, and they will receive routine medical check‑ups to monitor their overall health while using the medication.

The purpose of the trial is to determine whether MK-1045 can achieve a higher rate of complete remission (no detectable cancer) and improve overall survival (how long participants live) compared with blinatumomab. Participants will receive a series of treatment cycles lasting several weeks, during which doctors will monitor for adverse events (side effects) and check for minimal residual disease negativity (absence of tiny amounts of cancer cells). Some participants may later undergo allogeneic hematopoietic stem cell transplantation, a procedure that replaces diseased blood‑forming cells with healthy ones from a donor, if deemed appropriate by their physicians.

The goal of the trial is to find out whether adding Venetoclax to the standard three‑drug mix can improve overall survival, which means living longer after the treatment starts.

In this phase 3 study, children are placed by chance into one of two groups: one group receives the three standard drugs, and the other group receives the same three drugs plus the oral Venetoclax. Treatment is given in cycles over several weeks, and the children are checked regularly to see how they are doing and to record any side effects. The study follows each participant for a period of time to see how long they live and how they feel.

The main purpose of the trial is to keep participants who are still benefiting from the drug under medical supervision while safety is monitored. After joining, participants will continue to receive opnurasib on a regular schedule for as long as it remains helpful and tolerable. Visits will include simple check‑ups to record any side effects, any changes in dosage, and overall health. The study does not involve any additional invasive procedures beyond the usual care for this condition.

The purpose is to determine whether early vaccination changes how strong the immune protection is later, measured by the amount of neutralising antibodies against measles several years after the routine dose given at age 4. Children are followed for up to three years after that routine dose, and blood samples are tested using a plaque-reduction neutralisation test and also to assess levels of IgG, a protein that shows immune memory. The study follows each child through the early vaccination, the routine dose, and the later check‑ups without requiring special procedures beyond routine clinic visits.

On the day of surgery, the drug is given and then the patient undergoes either a minimally invasive robotic removal of the throat tumor using transoral robotic surgery or a removal of lymph nodes in the neck with neck dissection surgery. During the operation the surgeon watches the glowing signal and notes whether cancer is visible. After removal, the tissue is examined under a microscope to confirm whether the glowing areas matched the cancer. The study follows each participant for a short period after surgery to collect the imaging and pathology results.

The purpose of the trial is to compare how well the new medicine works against the standard treatment in shrinking tumors and helping patients live longer. Participants will be randomly assigned to one of the two treatment arms and will receive the assigned therapy in repeated cycles every few weeks. Throughout the study, doctors will perform regular safety checks, blood tests, and imaging scans to see how the disease responds, and they will record any side effects that occur.

The purpose of the study is to evaluate whether the new medicine can lower the number of treated bleeds compared with standard therapy. Participants will be assigned to receive either the new medicine or the standard factor VIII for about six months, attending regular visits where any bleeding events are recorded, quality‑of‑life questionnaires are completed, and safety checks such as blood tests for antibodies or reactions at the injection site are performed. The trial will monitor how often injections are needed, the amount of medicine used, and any side effects that arise during the treatment period.

Participants are randomly assigned to receive either a daily oral pill such as edoxaban or apixaban, an injectable medicine such as dalteparin, tinzaparin, enoxaparin, or rivaroxaban, or a placebo that looks the same but contains no active drug. Over several months, they will have regular check‑ups that may include simple scans of the lungs to confirm whether the clot has changed, and they will complete questionnaires about their daily well‑being. The study does not require any special procedures beyond the usual care for cancer and clot management.

Participants in the study will be randomly assigned to receive either cabozantinib plus supportive care or just supportive care. The study will monitor the participants over a period to see how the treatment affects the progression of the disease. The trial will also assess the safety of cabozantinib and how the body processes the drug, which is known as pharmacokinetics. The study will involve regular check-ups and assessments to track the health and progress of the participants.

The trial aims to provide valuable information on whether cabozantinib can help improve the outcomes for young people with osteosarcoma. The study will last for several months, and participants will be closely monitored throughout the process to ensure their safety and to gather data on the effectiveness of the treatment. The results of this study could potentially lead to better treatment options for those affected by this challenging condition.

The purpose of the study is to understand how safe and tolerable the new treatment is for patients, as well as to see how well it works in reducing the size of the cancer. Participants in the study will receive the investigational treatment, and their response to the treatment will be monitored over time. The study will also look at how long any positive effects of the treatment last.

Throughout the study, researchers will keep track of any side effects experienced by participants and whether these side effects lead to stopping the treatment. The study aims to gather important information that could help in developing new treatment options for people with this type of cancer. The trial is expected to continue until early 2028.

The purpose of the study is to evaluate how well AVP-786 works in reducing agitation symptoms in patients with Alzheimer’s-related dementia. Participants in the study will receive either the AVP-786 capsules or a placebo, and neither the participants nor the researchers will know which treatment each participant is receiving. This is known as a double-blind study. The study will take place over a period of time, during which participants will be monitored for changes in their symptoms and any side effects they may experience.

Throughout the study, participants will be asked to take the medication orally, in capsule form, and will be regularly assessed by healthcare professionals. The study aims to provide valuable information on whether AVP-786 can be a beneficial treatment option for managing agitation in patients with Alzheimer’s disease. The results will help determine if this medication can improve the quality of life for those affected by this condition.

The purpose of the study is to learn about the safety of BIIB080 and whether it can improve symptoms in participants. Participants will receive the treatment through an injection into the spinal fluid, a method known as intrathecal use. The study will last for a period of 76 weeks, during which participants will be monitored for changes in their cognitive abilities and overall health. The study aims to understand how different doses of the treatment affect the symptoms of Alzheimer’s disease.

Throughout the study, participants will undergo various assessments to track their progress. These assessments include tests to measure memory and thinking skills, as well as monitoring for any side effects or adverse events. The study is designed to provide valuable information on the potential benefits and safety of BIIB080 for individuals with early stages of Alzheimer’s disease.

People in the study are assigned by chance to receive either acetylcysteine or sodium chloride. The treatment is given during the hospital stay, and the study then follows the course of recovery over the next days and months. The study looks at how well participants do after treatment, including survival and length of hospital stay, without using complicated procedures in the description.

Sepsis is a serious reaction to infection that can quickly become life-threatening. Liver dysfunction means the liver is injured or not working normally. The purpose of this study is to assess whether acetylcysteine can help adults with severe infection and liver dysfunction recover better.

The purpose of the study is to determine if niraparib can help patients live longer without the disease getting worse, compared to temozolomide. Participants in the study will be randomly assigned to receive either niraparib or temozolomide. The study will monitor the participants over time to see how the treatments affect their health and the progression of their glioblastoma.

Throughout the study, researchers will also look at how the treatments impact overall survival, which means the length of time patients live after starting the treatment. Additionally, the study will assess the participants’ symptoms, quality of life, and any side effects they may experience. This information will help determine the safety and effectiveness of niraparib compared to temozolomide for treating this specific type of glioblastoma.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The study follows people who have already completed an earlier asciminib study and are considered by the doctor to still benefit from treatment. Treatment is continued over time, and regular study visits are planned so that health and any side effects can be watched. The study looks at possible adverse events, which are unwanted health problems that happen during treatment, and serious adverse events, which are more severe health problems. In some parts of the study, other tyrosine kinase inhibitors that may have been used in earlier studies include nilotinib, dasatinib, imatinib, and bosutinib.

The study is designed to provide continued access to the same study treatment received before while long-term safety is followed over time.

The purpose of the trial is to evaluate the safety and efficacy of the new combination therapy. Over a period of about four weeks, subjects will take the study medication once daily, while other participants receive a matching placebo. Safety will be monitored through reports of any side effects, regular blood tests, standard 12‑lead ECG recordings to check heart rhythm, and measurements of Sweat chloride levels, which reflect how the disease is affecting the body.

Effectiveness will be assessed by measuring lung function using the percent predicted forced expiratory volume in one second (ppFEV1) and by having participants complete a disease‑specific questionnaire that evaluates breathing symptoms (CFQ R). The study involves several clinic visits for these tests and for overall health checks.

People in the study are placed into one of the treatment groups by chance. Treatment is given as intravenous infusion, which means medicine is delivered slowly through a vein. The study is planned to follow people over time while they receive treatment and after treatment ends to see how they do. The trial also watches for side effects, including cytokine release syndrome, a strong immune reaction, and ICANS, which is a group of brain and nerve symptoms that can happen with some immune treatments.

Obrixtamig is also known by the code name BI 764532. It is a type of treatment called a T cell engager, which is designed to help the immune system find and attack cancer cells that have DLL3 on their surface. The study is for previously untreated cancer that is DLL3-positive, meaning the cancer cells have this marker.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

This is an extension study, which means it follows people who have already taken KL1333 or placebo in a previous study. During the study, the medicine is taken for about 48 weeks, and health checks are done throughout the study to watch for side effects and other safety issues. The study also looks at how people feel and function in daily life, including tiredness, movement, and overall health.

Primary mitochondrial disease can cause muscle weakness, severe tiredness, exercise problems, and other body-wide symptoms because the cells do not produce enough energy. The study is focused on adults with this condition, and the medicine is given as a tablet taken orally, meaning by mouth.